Loading…
Vaishali Pharma (VAISHALI)₹7.02+1.01%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Vaishali Pharma reported sales of ₹22.91 Cr and net profit of ₹1.56 Cr. For the year to Mar 2026, sales were ₹109 Cr and net profit ₹4.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 33.44 | 24.67 | 26.92 | 22.91 |
| Expenses | 31.92 | 23.01 | 27.04 | 21.33 |
| Operating Profit | 1.38 | 1.55 | −0.19 | 1.48 |
| OPM % | 4.2% | 6.3% | −0.7% | 6.5% |
| Other Income | 0.83 | 0.88 | 1.25 | 0.57 |
| Interest | 0.39 | 0.50 | 0.71 | 0.19 |
| Depreciation | 0.16 | 0.12 | 0.15 | 0.13 |
| Profit before tax | 1.65 | 1.80 | 0.17 | 1.72 |
| Tax % | 28.4% | 28.3% | −61.1% | 13.9% |
| Net Profit | 1.20 | 1.33 | 0.42 | 1.56 |
| EPS (Rs) | 0.08 | 0.09 | 0.02 | 0.11 |
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 109 | 108 |
| Expenses | 105 | 103 |
| Operating Profit | 3.99 | 4.22 |
| OPM % | 3.8% | 3.9% |
| Other Income | 3.99 | 3.53 |
| Interest | 1.99 | 1.79 |
| Depreciation | 0.99 | 0.56 |
| Profit before tax | 4.99 | 5.34 |
| Tax % | 25.1% | — |
| Net Profit | 4.01 | 4.51 |
| EPS (Rs) | 0.31 | 0.30 |
| Dividend payout % | 0.0% | — |
| Mar 2026 | |
|---|---|
| Equity Capital | 25.99 |
| Reserves | 43.17 |
| Borrowings | 19.03 |
| Other Liabilities | 35.17 |
| Total Liabilities | 123 |
| Fixed Assets | 2.01 |
| CWIP | 0.00 |
| Investments | 6.02 |
| Other Assets | 116 |
| Inventories | 2.99 |
| Trade receivables | 50.79 |
| Cash & equivalents | 1.01 |
| Total Assets | 123 |
| Mar 2026 | |
|---|---|
| Debtor days | 170 |
| Inventory days | 12 |
| Days payable | 80 |
| Cash conversion cycle | 101 |
| Working capital days | 212 |
For the Jun 2026 quarter, Vaishali Pharma reported sales of ₹22.91 Cr and net profit of ₹1.56 Cr. The operating margin was 6.5%.
Vaishali Pharma's sales for the year to Mar 2026 were ₹109 Cr; over the last twelve months they were ₹108 Cr.
Net profit for the year to Mar 2026 was ₹4.01 Cr, and ₹4.51 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.30.
Vaishali Pharma reported borrowings of ₹19.03 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.